Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xilio Therapeutics (Nasdaq: XLO) said company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 9, 2026 at 3:00 p.m. ET.
A live webcast will be available at the company investor site ir.xiliotx.com, with a replay archived for 30 days after the presentation.
Details
News Market Reaction – XLO
On Mar 2, the day this news came out, XLO closed 2.37% above the previous close.
Data tracked by StockTitan Argus for the Mar 2 session.
Key Figures
- Conference date
- March 9, 2026
- Leerink Partners Global Healthcare Conference fireside chat
- Presentation time
- 3:00 p.m. ET
- Scheduled time for the fireside chat
- Webcast replay period
- 30 days
- Duration the conference webcast replay will be available
Historical Context
-
Underwritten offering of pre-funded warrants raising about $40M gross proceeds.
-
Cash runway into Q2 2027 and program milestones plus board leadership change.
-
Q3 2025 results with positive vilastobart and XTX501 updates and solid cash.
-
Late-breaking Phase 2 vilastobart data showing 40% ORR in selected MSS mCRC.
-
SITC 2025 showcase of masked immunotherapy platform and early clinical results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
immuno-oncology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat during the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET.
A live webcast can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary masking technology to advance a pipeline of novel, masked I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.